Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) / Musolino, A; Gori, S; Cavanna, L; Graiff, C; Frassoldati, A; Bria, E; Bisagni, G; Zambelli, A; Partesotti, G; Brandes, A; Bonetti, A; Moscetti, L; Zamagni, C; Rocca, A; Generali, D; Montemurro, F; Gianni, L; Tognetto, M; Maglietta, G; Todeschini, R. - In: CANCER RESEARCH. - ISSN 1538-7445. - (2018), pp. OT1-03-03-OT1-03-03. [10.1158/1538-7445.SABCS17-OT1-03-03]
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Musolino, A
Writing – Review & Editing
;
2018-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.